Idiopathic Pulmonary Fibrosis: all 565 studies

Page 2 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary FibrosisRecruitingNCT04619199Not applicable
• Cohort of IPF Patients Experiencing an ExacerbationRecruitingNCT04442711
• Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisRecruitingNCT04362644Phase 1
• Longitudinal Changes in Serum KL-6 in IPFRecruitingNCT04268485
• Korean Idiopathic Pulmonary Fibrosis RegistryRecruitingNCT04160715
• The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) StudyEnrolling by invitationNCT04016181
• Skeletal Muscle Function in Interstitial Lung DiseaseRecruitingNCT03800017Not applicable
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingNCT03500731Phase 1/2
• The Genetics of Pulmonary FibrosisRecruitingNCT03478553
• Mechanisms of Familial Pulmonary FibrosisRecruitingNCT03437486
• Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseRecruitingNCT03297775
• Controls for Respiratory DiseasesRecruitingNCT03120481
• Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes RegistryRecruitingNCT01915511
• Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesRecruitingNCT01776398
• Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT01088217
• A Study of the Natural Progression of Interstitial Lung Disease (ILD)RecruitingNCT00470327
• Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT00373841
• Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and NintedanibCompletedNCT06717100Phase 1Results posted
• A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT06317285Phase 2Results posted
• A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking NintedanibCompletedNCT06200714Results posted
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Phase 2Results posted
• The Effect of N115 on Coughing in IPF PatientsCompletedNCT06037408Phase 3Results posted
• Cough Reduction in IPF With Nalbuphine ERCompletedNCT05964335Phase 2Results posted
• A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) PatientsCompletedNCT05954988Phase 1Results posted
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Phase 2Results posted
• Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) PatientsCompletedNCT05870956Results posted
• Dose Reduction and Discontinuation With Anti-Fibrotic MedicationsCompletedNCT05779007Results posted
• Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)CompletedNCT05621252Phase 2Results posted
• Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisCompletedNCT05537025Phase 1/2Results posted
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).CompletedNCT05513950Phase 1Results posted
• To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPFTerminatedNCT05497284Phase 2Results posted
• First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy SubjectsCompletedNCT05427253Phase 1Results posted
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Phase 3Results posted
• Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT05255991Phase 3Results posted
• Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary FibrosisCompletedNCT05185089Phase 2Results posted
• Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisCompletedNCT05130970Phase 2Results posted
• A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT05032066Phase 2Results posted
• Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis PatientsCompletedNCT05022784Results posted
• A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Phase 3Results posted
• Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFCompletedNCT04533022Phase 2Results posted
• Safety and Effectiveness of Nintedanib in Korean PatientsCompletedNCT04525547Results posted
• Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis CoughCompletedNCT04429516Phase 3Results posted
• Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Phase 3Results posted
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT04419506Phase 2Results posted
• Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT04396756Phase 2Results posted
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedNCT04308681Phase 2Results posted
• Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/CompletedNCT04072315Phase 2Results posted
• Genentech Xenon MRI Idiopathic Pulmonary FibrosisCompletedNCT04071769Phase 2Results posted
• A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughCompletedNCT04030026Phase 2Results posted
• A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are TakingCompletedNCT03958071Results posted
• Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Phase 3Results posted
• Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.CompletedNCT03928847Early Phase 1Results posted
• GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisCompletedNCT03865927Phase 2Results posted
• A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT03832946Phase 2Results posted
• Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary FibrosisTerminatedNCT03744598Results posted
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03733444Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary FibrosisCompletedNCT03727802Phase 1Results posted
• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT03725852Phase 2Results posted
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03717012Phase 4Results posted
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareTerminatedNCT03711162Phase 3Results posted
• Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With NintedanibCompletedNCT03710824Results posted
• Families-At-risk for Interstitial Lung Disease StudyCompletedNCT03641742Results posted
• An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT03573505Phase 2Results posted
• Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03562247Not applicableResults posted
• JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPFCompletedNCT03538301Phase 2Results posted
• Digital Auscultation Test - IPF Data CollectionCompletedNCT03503188Phase 4Results posted
• This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.CompletedNCT03422068Phase 1Results posted
• OASIS-IPF (Idiopathic Pulmonary Fibrosis) StudyCompletedNCT03386994Results posted
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary FibrosisTerminatedNCT03287414Phase 2Results posted
• Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary FibrosisCompletedNCT03286556Phase 2Results posted
• Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in SpainCompletedNCT03281200Results posted
• A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic PeriodCompletedNCT03261037Not applicableResults posted
• Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).CompletedNCT03208933Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedNCT03142191Phase 2Results posted
• Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary FibrosisCompletedNCT03104322Not applicableResults posted
• Investigating Idiopathic Pulmonary Fibrosis in GreeceCompletedNCT03074149Results posted
• Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) ImagingTerminatedNCT03069989Phase 1Results posted
• Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary FibrosisCompletedNCT03047031Results posted
• Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at RestTerminatedNCT02989168Phase 2Results posted
• Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary HypertensionCompletedNCT02951429Phase 2Results posted
• A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02871401Phase 1Results posted
• Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPFCompletedNCT02846324Phase 2Results posted
• IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary FibrosisCompletedNCT02803580Results posted
• Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function ImpairmentCompletedNCT02802345Phase 3Results posted
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentCompletedNCT02788474Phase 4Results posted
• CleanUP IPF for the Pulmonary Trials CooperativeTerminatedNCT02759120Phase 3Results posted
• Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02738801Phase 2Results posted
• A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02707640Phase 2Results posted
• A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02688647Phase 2Results posted
• All-Case Surveillance of Ofev in Patients With IPF in JapanCompletedNCT02607722Results posted
• A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in CombinationCompletedNCT02606877Phase 4Results posted
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02598193Phase 4Results posted
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedNCT02579603Phase 4Results posted
• A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02550873Phase 2Results posted
• Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisCompletedNCT02503657Phase 2Results posted
• A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)CompletedNCT02502097Phase 2Results posted
• A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02477709Phase 2Results posted
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02345070Phase 2Results posted

← Idiopathic Pulmonary Fibrosis overview